Joseph Schwartz Recent News
Arena Pharma Could Be Developing Several Best-In-Class Agents
Do Analysts See A Path Forward For Ophthotech's Fovista?
Sarepta Stock Has Fully Consolidated; Leerink Upgrades To Outperform
Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
2 Opposing Views On The Future Of Sarepta
3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
Leerink Raises Ultragenyx Pharma's Price Target On Confidence In MPS 7 Treatment
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
Why Leerink Is Cutting Biogen Targets (But Still Bullish On The Stock)
Is BioMarin A Buy Ahead Of This Important Data Release?
GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success
UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results